Novel optimised quinuclidine squalene synthase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 5, 1997, Pages 597-600

  Brown, George R ^a   Foubister, Alan J ^a   Freeman, Susan ^a   McTaggart, Fergus ^a   Mirrlees, Donald J ^a   Reid, Alan C ^a   Smith, Graham J ^a   Taylor, Melvyn J ^a   Thomason, Douglas A ^a   Whittamore, Paul R O ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [2 ALLYL 4 (2 ETHOXYCARBONYLETHYL)PHENYL]VINYL]QUINUCLIDIN 3 OL; ENZYME INHIBITOR; QUINUCLIDINE DERIVATIVE; SQUALENE SYNTHASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG METABOLISM; DRUG SYNTHESIS; ENANTIOMER; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; HYDROLYSIS; IN VITRO STUDY; LIPOPHILICITY; LIVER; MICROSOME; NONHUMAN; ORAL DRUG ADMINISTRATION; PLASMA; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALIA;

EID: 0031552147     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)00053-X     Document Type: Article

References (15)

1. (1) Pedersen, T. R.; Kjekshus, J.; Berg, K.; Haghfelt, T.; Fargeman, O.; Thorgeirsson, G.; Pyorala, K.; Mertinen, T.; Olsson, A.G.; Wedel, H.; Wilhelmsmen, L. Lancet, 1994, 344, 1383-1389.
2. (2) Shepherd, J; Cobbe, S. M.; Ford, I.; Isles, C. G.; Lorimer, A. R.; Macfarlane, P. W.; McKillop, J. H.; Packard, C.J. New Engl. J. Med., 1995, 333, 1301-1307.
3. (3) Biller, S. A.; Neuenschwander, K.; Ponpipom, M. M.; Poulter,C. D. Cur. Pharm. Des., 1996, 2, 1-40.
4. (4) a) Watson, N. S.; Procopiou, P. A. Progress in Medicinal Chemistry, Eds. Ellis. G. P.; Luscombe, D. K. 1996, 33, 331-378;
5. b) Biller, S. A.; Ciosek, Jr., C. P.; Dickson, Jr., J. K.; Gordon, E. M.; Harrity, T.; Hamilton, K. A.; Jolibois, K. G.; Kunselman, A. K.; Lawrence, M.; Mookhtiar, K. A.; Rich, L. C.; Slusarchyk, D. A.; Sulsky, R. B. J. Biol. Chem., 1993, 268, 24832-24837;
6. c) Biller, S. A.; Ying, C.; Fryszman, O. M.; Lawrence, R. M.; Logan, J. V. H.; Dickson, Jr., J. K.; Magnin, D. R.; Sieber-McMaster, E. S.; Sulsky, R. B.; Traeger, S. C.; Hsieh, D. C.; Shih-Jung, L.; Rinehart, J. K.; Harrity, T. W.; Jolibois, K. J.; Kunselman, L. K.; Rieh, L. C.; Slusarchyk, D. K.; Ciosek, Jr, C. P. J. Med. Chem., 1996, 39, 657-660.
7. d) Biller, S. A.; Dickson, Jr., J. K.; Magnin, D. R.; Pertillo, Jr., E. W.; Hillyer, J. W.; Hsieh, D. C.; Shih-Jung, L.; Rinehart, J. K.; Gregg, R. E.; Harrity, T. W.; Jolibois, K. J.; Kalinowski, S. S.; Kunselman, L. K.; Mookhtiar, K. A.; Ciosek, Jr., C. P. J. Med. Chem., 1996, 39, 661-664.
8. (5) a) Brittain, D. R.; Brown, G. R.; Whittamore, P. R. O. PCT Int. Appl. WO 9425459 A1 941110; Chem. Abstr. 1995, 123, 169513;
9. (5) a) Brittain, D. R.; Brown, G. R.; Whittamore, P. R. O. PCT Int. Appl. WO 9425459 A1 941110; Chem. Abstr. 1995, 123, 169513;
10. b) Brown, G. R.; Clarke, D. S.; Foubister, A. J.; Freeman, S.; Harrison, P. J.; Johnson, M. C.; Mallion, K. B.; McCormick, J.; McTaggart, F.; Reid, A. C.; Smith, G. J.; Taylor, M. J. J. Med. Chem. 1996, 39, 2971-2979;
11. c) McTaggart, F.; Brown, G. R.; Davidson, R. G.; Freeman, S.; Holgate, G. A.; Mallion, K. B.; Mirrlees, D. G.; Smith, G. J.; Ward, W. H. J. Biochem. Pharmacol., 1996, 51, 1477-1487.
12. (6) Poulter, C. D.; Rilling, H. C. Biosynthesis of Isoprenoid Compounds, Eds. Porter, J. W.; Spurgeon, W. Wiley, New York, 1981, 1, 414-441.
13. (7) Poulter C. D.; Capson, T. L.; Thompson, M. D.; Bard, R. S. J. Am. Chem. Soc., 1989, 111, 3734-3739.
14. 3) δ ppm 1.22 (t, 3H), 1.34-1.50 (m, 1H), 1.57-1.72 (m, 1H), 1.90-2.15 (m, 3H), 2.55-2.65 (t, 3H), 2.75-2.95 (m, 6H), 3.08 (d, 1H), 3.31 (d, 1H), 3.51 (d, 2H), 4.12 (q, 2H), 4.98-5.10 (m, 2H), 5.86-6.03 (m, 1H), 6.97-7.05 (m, 2H), 7.32 (d, 1H); EI-MS m/z 368 (M+H).
15. (9) Biller, S. A.; Forster, C.; Gordon, E. M.; Harrity, T.; Rich, L. C.; Marreta, J.; Ciosek, Jr, C. P. J. Med. Chem., 1991, 34, 1912-1914.